- Home
- HRZN vs VCRE Comparison
HRZN vs VCRE Comparison
Compare HRZN & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HRZN | VCRE |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | Sweden |
| Employees | N/A | 40 |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.2M | 332.9M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRZN | VCRE |
|---|---|---|
| Price | $5.11 | $12.30 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 615.6K | 2.4K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 33.85% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.25 | N/A |
| Revenue Next Year | $22.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $10.50 |
| 52 Week High | $7.19 | $12.85 |
Technical Indicators
Market Signals| Indicator | HRZN | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 71.77 | 48.32 |
| Support Level | $3.93 | $11.00 |
| Resistance Level | $6.77 | $12.85 |
| Average True Range (ATR) | 0.15 | 0.31 |
| MACD | 0.07 | 0.14 |
| Stochastic Oscillator | 95.85 | 75.89 |
Price Performance
Historical ComparisonAbout HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.